Gyre Therapeutics, Inc. (GYRE) compared with its closest peers (ASRT, URGN, XNCR, ZVRA, KPTI). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Assertio, UroGen Pharma, Xencor, Zevra Therapeutics, Karyopharm Therapeutics, MacroGenics, Cytokinetics, Nurix Therapeutics, Arcturus Therapeutics and Eton Pharmaceuticals share Gyre Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Assertio Holdings, Inc. (ASRT) | $151.83M | -1.9 |
| UroGen Pharma Ltd. (URGN) | $2.28B | -7.3 |
| Xencor, Inc. (XNCR) | $2.06B | -12.3 |
| Zevra Therapeutics, Inc. (ZVRA) | $701.40M | 6.4 |
| Karyopharm Therapeutics Inc. (KPTI) | $44.57M | -0.4 |
| MacroGenics, Inc. (MGNX) | $257.35M | -1.4 |
| Cytokinetics, Incorporated (CYTK) | $10.69B | -9.7 |
| Nurix Therapeutics, Inc. (NRIX) | $2.77B | -5.8 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $382.29M | -2.5 |
| Eton Pharmaceuticals, Inc. (ETON) | $1.81B | 142.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
GYRE overview · GYRE earnings · GYRE financials · GYRE KPIs · GYRE documents · GYRE ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.